Choose Your Country or Region

Anti-Phospho-AMPA Receptor 1 (GluA1) (Ser831) Rabbit Antibody [D9B24]

Catalog No.: F4092

Application: Reactivity: Human, Mouse

Usage Information

Dilution
WB1:1000 IP1:50

Application
WB, IP

Reactivity
Human, Mouse

Source
Rabbit

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
100 kDa

Positive Control	Mouse brain
Negative Control

Datasheet & SDS

Biological Description

Specificity
Anti-Phospho-AMPA Receptor 1 (GluA1) (Ser831) Rabbit Antibody [D9B24] recognizes endogenous levels of AMPA Receptor 1 (GluA1) protein only when phosphorylated Ser831.

Clone
D9B24

Synonym(s)
Glutamate receptor 1, GluR-1, AMPA-selective glutamate receptor 1, GluR-A , GluR-K1, Glutamate receptor ionotropic, AMPA 1, GRIA1, GLUA1, GLUH1, GLUR1

Background
Ionotropic glutamate receptors are categorized into three major families: AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid), kainate, and NMDA (N-methyl-D-aspartate) receptors. Among these, AMPA receptors (AMPARs), composed of four subunits (GluA1–4) arranged as homo- or hetero-tetramers, mediate the bulk of fast excitatory neurotransmission in the central nervous system. AMPARs play essential roles in synapse development, stabilization, and synaptic plasticity. Their functional diversity arises from both post-transcriptional modifications (such as alternative splicing and RNA editing) and post-translational modifications (including glycosylation and phosphorylation), which collectively fine-tune AMPAR kinetics. Dysregulation of AMPAR activity has been associated with several neurological disorders, including Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), stroke, and epilepsy. Specifically, the GluA1 subunit undergoes phosphorylation at Ser831 and Ser845, which critically regulates receptor activity and synaptic plasticity. CaMKII and PKC phosphorylate Ser831, while PKA targets Ser845. Phosphorylation at these sites enhances AMPAR ion channel function: long-term potentiation (LTP) is linked to increased phosphorylation, whereas long-term depression (LTD) correlates with GluA1 dephosphorylation.

Background

Ionotropic glutamate receptors are categorized into three major families: AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid), kainate, and NMDA (N-methyl-D-aspartate) receptors. Among these, AMPA receptors (AMPARs), composed of four subunits (GluA1–4) arranged as homo- or hetero-tetramers, mediate the bulk of fast excitatory neurotransmission in the central nervous system. AMPARs play essential roles in synapse development, stabilization, and synaptic plasticity. Their functional diversity arises from both post-transcriptional modifications (such as alternative splicing and RNA editing) and post-translational modifications (including glycosylation and phosphorylation), which collectively fine-tune AMPAR kinetics. Dysregulation of AMPAR activity has been associated with several neurological disorders, including Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), stroke, and epilepsy. Specifically, the GluA1 subunit undergoes phosphorylation at Ser831 and Ser845, which critically regulates receptor activity and synaptic plasticity. CaMKII and PKC phosphorylate Ser831, while PKA targets Ser845. Phosphorylation at these sites enhances AMPAR ion channel function: long-term potentiation (LTP) is linked to increased phosphorylation, whereas long-term depression (LTD) correlates with GluA1 dephosphorylation.

References
https://pubmed.ncbi.nlm.nih.gov/15914469/ https://pubmed.ncbi.nlm.nih.gov/10879537/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%